The centers will work with academic institutions to accelerate discovery research that will address the world's most pressing global health challenges. The first J&J Satellite Center for Global Health Discovery was launched at the London School of Hygiene & Tropical Medicine, and additional J&J Centers will launch worldwide through 2022.

Each satellite center will focus on entrenched and emerging threats that have a high unmet need, including tuberculosis, dengue fever, flavivirus, coronavirus, and antimicrobial resistance. The centers will fund early-stage science, innovation, and talent development.

Following review, FDA lifts J&J COVID-19 vaccine pause
Johnson & Johnson's COVID-19 vaccinations are set to resume in the U.S. following a decision by the U.S. Food and Drug Administration (FDA) and the...

Europe resumes use of J&J COVID-19 vaccine after EMA review
Rollout of the COVID-19 vaccine from Johnson & Johnson will resume after the European Medicines Agency (EMA) confirmed that the vaccine's overall...

Janssen COVID-19 vaccine nearing European approval
Johnson & Johnson announced it has moved a step closer toward marketing authorization for its single-dose COVID-19 vaccine candidate in Europe.

J&J single-shot COVID-19 vaccine meets end points
Johnson & Johnson released efficacy and safety data from its phase III Ensemble clinical trial, which demonstrates that the investigational single-dose...

U.S. government expands assistance to J&J COVID-19 vaccine research
The Biomedical Advanced Research and Development Authority is expanding its partnership with Johnson & Johnson by providing additional support for...